ARA-290
ARA-290Erythropoietin-derived peptide studied in repair.
Also known as: Cibinetide
Overview
ARA-290 (cibinetide) is a peptide derived from the erythropoietin molecule studied in tissue-protection, neuropathy, and inflammation research.
An 11-amino-acid peptide derived from the structure of erythropoietin (EPO) that activates the tissue-protective innate repair receptor without EPO's effects on red-blood-cell production. Studied for anti-inflammatory and neuropathic-pain applications, notably in sarcoidosis-related small-fiber neuropathy.
Activates the innate repair receptor (a complex of the EPO receptor and beta-common receptor) without affecting red-blood-cell production.
Molecular information
Cibinetide (pyroglutamate-EQLERALNSS)Mimics the spatial structure of EPO's helix B without erythropoietic activity.
Pharmacokinetics
Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.
Research applications
- Tissue-protection research
- Neuropathy studies
- Inflammation-resolution investigations
Research protocols
Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.
Observed effects timeline
Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.
Week 1–4
Anti-inflammatory and neuroprotective signaling reported in study models.
Week 4–12
Changes in neuropathic-pain and small-fiber markers reported in research.
Research compatibility
Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.
BPC-157
Complementary repair/anti-inflammatory pathways.
Thymosin Beta-4
Distinct repair mechanisms.
KPV
Complementary anti-inflammatory signaling.
How to reconstitute
Reconstitute with bacteriostatic water, swirl gently, and refrigerate. Avoid shaking to preserve the peptide.
- 1Allow the vial to reach room temperature (15–20 minutes).
- 2Swab the stopper with alcohol and let it air dry.
- 3Add bacteriostatic water slowly down the vial wall.
- 4Swirl gently until dissolved into a clear solution.
- 5Refrigerate at 2–8 °C and protect from light.
Quality indicators
Uniform white powder
Lyophilized cake should be white to off-white without discoloration.
Clear solution
Reconstitutes to a clear, colorless, particle-free solution.
Cold-chain integrity
Reconstituted solution requires 2–8 °C storage.
Slight clumping
Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.
Collapsed or melted appearance
Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.
Cloudy after reconstitution
Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.
Reported observations & safety
Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.
- Notably does not raise hematocrit, unlike EPO — a key part of its research rationale.
- Generally reported as well tolerated; mild injection-site reactions are the most common signal.
References & further reading
ARA-290 (cibinetide) in sarcoidosis neuropathy (clinical)
Research reporting improvements in small-fiber neuropathy symptoms with the EPO-derived peptide.
View studyTopics
This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.
Active but early-stage research; evidence still developing.
This compound is part of our educational reference and is not currently stocked. Browse the catalogue for available research-grade peptides.
Browse catalogue